Semax
BDNF Upregulation & Neuroprotective Signaling
What is Semax?
Semax is a synthetic heptapeptide developed in Russia, structurally based on a fragment of adrenocorticotropic hormone — specifically the ACTH(4-10) sequence — with a proline-glycine-proline tail added to increase its resistance to enzymatic degradation. Importantly, Semax retains the neuroactive properties of the ACTH fragment while lacking its hormonal (corticotropic) activity, which is central to why it is studied as a neuropeptide rather than as a hormone. In the Russian medical and research literature it has a long history as a subject of investigation in cognition, neuroprotection, and recovery from cerebrovascular events.
The most frequently cited mechanism in the preclinical literature is upregulation of neurotrophic factors, particularly brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), along with changes in the expression of genes involved in neuroplasticity, synaptic function, and cellular stress responses. Researchers have also examined effects on the dopaminergic and serotonergic systems, on inflammatory and antioxidant markers, and on the neurotrophic signaling cascade following ischemic or oxidative injury. In animal learning-and-memory paradigms, Semax has been reported to influence attention and memory-related performance, which underpins its characterization as a nootropic research compound. In Russia it has been studied in the context of ischemic stroke and cognitive disorders, though these studies fall largely outside the framework of large international clinical trials.
As with related Russian-developed neuropeptides, the evidence for Semax is concentrated in preclinical work and in clinical studies conducted primarily within Russia, and it has not undergone the kind of large, independently replicated trials common to internationally approved drugs. Its reported cognitive and neuroprotective effects should therefore be regarded as promising research findings rather than established outcomes. Semax is not an approved medication in most regulatory jurisdictions and is offered strictly for laboratory research and educational purposes only; nothing here is medical advice or intended to guide human use.
Molecular data
Mechanism of action
In preclinical research, Semax is associated with the following pathways and targets:
Research highlights
- Potent upregulation of BDNF and NGF expression
- Derived from ACTH(4-10) with enhanced stability
- Neuroprotective effects in ischemia and oxidative stress models
- Cognitive enhancement observed in preclinical learning paradigms
Frequently asked questions
What is Semax used for in research?
Semax is a synthetic peptide studied mainly for cognitive enhancement and neuroprotection. In the Russian research literature it has been examined in the context of learning and memory, attention, and recovery from ischemic events such as stroke. Most evidence is preclinical or from studies conducted within Russia, so its effects are best treated as research findings rather than proven outcomes.
How does Semax work?
The most commonly described mechanism is upregulation of neurotrophic factors, especially BDNF and NGF, along with effects on neuroplasticity-related gene expression and on dopaminergic and serotonergic signaling. It also shows antioxidant and anti-inflammatory readouts in injury models. These are proposed mechanisms observed in laboratory and animal studies.
Where does Semax come from chemically?
Semax is derived from ACTH(4-10), a fragment of adrenocorticotropic hormone, with an added proline-glycine-proline sequence to improve stability. This design preserves the fragment's neuroactive effects while removing its hormonal activity, which is why it is studied as a neuropeptide rather than as a hormone.
How is Semax different from Selank?
Both are Russian-developed heptapeptides, but Semax is based on the ACTH(4-10) hormone fragment and is studied mainly for cognition and neuroprotection, while Selank is derived from the immune peptide tuftsin and is studied primarily as an anxiolytic. They share an emphasis on BDNF-related signaling but differ in origin, sequence, and research focus.
Is Semax an approved drug?
Semax is used within a specific Russian regulatory context but has not undergone the large, independently replicated international trials typical of broadly approved medicines, and it is not approved in most jurisdictions. It is supplied for laboratory research and educational purposes only, and none of this information should be taken as medical advice or guidance for human use.
Source Semax at Purgo Labs
≥99% purity, third-party COA verification, and same-day fulfillment.
Shop Semax at Purgo Labs ↗Related compounds
For research and educational purposes only. Semax is not approved for human use by any regulatory authority, and nothing on this page constitutes medical advice, diagnosis, or treatment. Research findings referenced here are predominantly preclinical.